This week, Cato Research is attending the Cancer Vaccines meeting in Cambridge, MA on 29 and 30 June. The conference is the first meeting dedicated to progressing cancer vaccines to market and will feature 21 of the world’s leading experts in oncology and cancer vaccines. The cutting-edge agenda addresses the key developmental challenges in order to enhance the way in which we develop therapeutic cancer vaccines.
Cato Research Clinical Strategy Scientist Laura DiMichele will be presenting data from Cancer Advances’ Phase 3 clinical trial in pancreatic cancer*. The poster is titled, “A Prospective, Randomized, Double-Blind, Placebo Controlled, Group Sequential Trial of PAS for the Treatment of Pancreatic Cancer.” PAS, or Polyclonal Antibody Stimulator, is the company’s lead compound. PAS functions by stimulating the immune system in the recipient to produce endogenous polyclonal antibodies to gastrin without the risks and limitations associated with serum-derived polyclonal treatment or monoclonal antibody therapy. The results from this Phase 3 trial demonstrated that successful treatment with PAS significantly prolongs survival, may inhibit tumor progression, (as would be expected with cytostatic therapy) and significantly increases performance status. Further, PAS is safe and very well tolerated in the context of cancer therapies. PAS provides a new therapeutic option for patients with advanced pancreatic cancer who may not be suitable for or refuse cytotoxic chemotherapy.
*Cancer Advances is a wholly owned subsidiary of Cato BioVentures, the venture capital affiliate of Cato Research.
